HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text (PDF) All Versions of this Article: M200464-JLR200v1 44/6/1156    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Liu, S. M. Articles by Kritharides, L. Search for Related Content PubMed PubMed Citation Articles by Liu, S. M. Articles by Kritharides, L. Social Bookmarking                      What's this?

Journal of Lipid Research, Vol. 44, 1156-1166, June 2003
Copyright © 2003 by Lipid Research, Inc.

Cyclodextrins differentially mobilize free and esterified cholesterol from primary human foam cell macrophages

Sue M. Liu^1,*, Anne Cogny^1,*, Maaike Kockx^1,, Roger T. Dean, Katharina Gaus, Wendy Jessup and Leonard Kritharides^2,*,,**

^* Heart Research Institute, Camperdown, Sydney New South Wales, Australia
Macrophage Biology Group, Centre for Thrombosis and Vascular Research, University of New South Wales, Australia
University of Canberra, ACT, Australia
^** Department of Cardiology, Concord Hospital, University of Sydney, Australia

Published, JLR Papers in Press, April 1, 2003. DOI 10.1194/jlr.M200464-JLR200

¹ S. M. Liu, A. Cogny, and M. Kockx contributed equally to this work.

² To whom correspondence should be addressed. e-mail: l.kritharides{at}unsw.edu.au

	ABSTRACT

TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
Human monocyte-derived foam cell macrophages (HMFCs) are resistant to cholesterol efflux mediated by physiological acceptors. The role of the plasma membrane in regulating depletion of free cholesterol (FC) and of cholesteryl ester (CE) was investigated using cyclodextrins (CDs). HMFCs were incubated in media containing CDs (1.0 mg/ml, 0.7 mM) with low [hydroxypropyl-ß-CD (HP-CD)] or high [trimethyl-ß-CD (TM-CD)] affinity for cholesterol in the presence or absence of phospholipid vesicles (PLVs). Low-affinity HP-CD caused minimal cholesterol efflux on its own, but HP-CD+ PLV depleted cell FC and CE to 54.5 ± 6.7% of control by 24 h. TM-CD depleted FC at least as well as HP-CD+PLV but without depleting CE, even when combined with PLV. This was not explained by acceptor saturation, instability of PLV vesicles, de novo cholesterol synthesis, kinetically distinct cholesterol pools, or inhibition of CE hydrolysis. TM-CD did, however, deplete CE when lower concentrations of TM-CD were combined with PLV and when acetyl-CoA cholesteryl acyltransferase was inhibited. TM-CD caused much greater depletion of plasma membrane cholesterol than HP-CD without depleting plasma membrane sphingomyelin.

It is concluded that differential depletion of plasma membrane cholesterol pools regulates cholesterol efflux and CE clearance in human macrophages.

Abbreviations: CD, cyclodextrin; CE, cholesteryl ester; FC, free cholesterol; HMFC, human monocyte-derived foam cell macrophage; HP-CD, hydroxypropyl-ß-CD; LPC, lysophosphatidylcholine; PC, phosphatidylcholine; PLV, phospholipid vesicles; SPM, sphingomyelin; TM-CD, trimethyl-ß-CD

Supplementary key words cholesterol efflux • high density lipoprotein • atherosclerosis • plasma membrane

	INTRODUCTION

TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
Human monocyte-derived foam cell macrophages (HMFCs) containing lipoprotein-derived free cholesterol (FC) and cholesteryl ester (CE) are a hallmark of atherosclerosis. In peripheral cells such as macrophages, excess accumulated cholesterol can be released into aqueous medium after conversion to more polar metabolites (for example, to 27OH-cholesterol) or released to a cholesterol acceptor such as HDL or apolipoprotein A-I (apoA-I) (1–3). Data from in vitro cell culture systems suggest that sterol release after metabolism is small relative to that released to cholesterol acceptors (4). The eventual delivery of cholesterol from the peripheral tissues to the liver for clearance in the bile is referred to as the reverse cholesterol transport pathway. This is recognized as one likely route by which HDL protects against the development of atherosclerosis.

The removal of cholesterol from cells has been broadly categorized as involving several processes: aqueous diffusion, lipid-free apolipoprotein membrane microsolubilization (5), and interaction with proteins ("receptors") located on the cell plasma membrane. As examples of the last of these, clearance of cholesterol from foam cells to HDL and its main protein constituent, apoA-I, have been identified as requiring interactions with the scavenger receptor type I (SR-BI) and the ATP-binding cassette transporter ABCA-1 protein, respectively (6–10). However, aqueous diffusion and acceptor-cell protein interactions are not mutually exclusive. For example, efflux to phospholipid vesicles (PLVs), which can accept cholesterol after its desorption into the aqueous layer, is enhanced from cells expressing SR-BI (11).

Data from several laboratories indicate that human macrophages are resistant to cholesterol efflux, at least in part due to slow mobilization of stored CEs by hydrolysis (12–14). In addition, as the flux of cholesterol through all cellular compartments is slow in human THP-1 macrophages (14), factors other than CE hydrolysis may also be limiting. Important earlier studies indicated that variations in rates of cholesterol efflux between different cell types and or different species were largely explained by differences in rates of efflux from the plasma membrane (15, 16). The processes that link the concentration of cholesterol in the plasma membrane with that of intracellular CE are complex (17–20), but studies generally indicate a close relationship between the cholesterol concentration of the plasma membrane and the mobilization of intracellular cholesterol.

Cyclodextrins (CDs) are cyclical oligomers of six, seven, or eight glucose molecules that can solubilize hydrophobic molecules such as cholesterol by virtue of their hydrophobic interior. Because CDs interact with the cell plasma membrane without internalization and do not disrupt membranes at low concentrations (and are thus unlike detergents) (21), they are useful for elucidating the role of plasma membrane pools of cholesterol in determining net cholesterol efflux and intracellular cholesterol metabolism (22, 23). In ß-CDs, which contain seven glucose molecules and most avidly bind cholesterol, the modification of CD side chains regulates their affinity for cholesterol. This determines the concentration at which CDs can cause effective cholesterol depletion from cells. CDs such as hydroxypropyl-ß-CD (HP-CD) and trimethyl-ß-CD (TM-CD) used at low concentrations mediate the removal of cholesterol and oxysterols from foam cells and from isolated membranes without toxicity and apparently without significant removal of cellular phospholipids or membrane proteins (21, 22, 24, 25).

CDs can cause the net removal of cholesterol from cells in one of two ways (26). First, they can accept cholesterol from the plasma membrane and retain it in the extracellular medium, acting as depots or "sinks." Second, at lower concentrations insufficient to alter net equilibrium between cells and medium, they can remove cholesterol from the plasma membrane and deliver it to a second acceptor of larger capacity but slower cholesterol efflux efficiency, such as PLV. In this instance, CDs act as vehicles or "shuttles" between cells and the terminal cholesterol sink (PLV). The latter process has also been identified in the removal of cholesterol by relatively small HDLs to large PLVs (27) and may apply to many other lipoproteins (28). Removal of cellular cholesterol by CDs by either mechanism permits investigation of the role of plasma membrane in net cholesterol efflux.

We have investigated cholesterol efflux from HMFC using high-affinity TM-CD ("sink") and low-affinity HP-CD in concert with PLV (HP-CD+PLV "shuttle") and identify the plasma membrane as a major rate-limiting site for cholesterol efflux and net CE clearance from HMFC. Significantly, we identify that depletion of cellular FC and CE are not necessarily linked. High-affinity TM-CD dissociates the clearance of FC and CE, and only HP-CD+PLV consistently depletes intracellular CE.

	MATERIALS AND METHODS

TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
Materials
Egg yolk phosphatidylcholine (PC), penicillin-streptomycin, essentially fatty-acid free BSA, and silica gel on polyester thin-layer chromatography (TLC) plates were from Sigma Aldrich. ß-CDs were from Cyclolabs (Hungary) and Sigma Aldrich. RPMI-1640 medium and glutamine were obtained from Gibco, and tissue culture plates and consumables were purchased from Falcon. [³H]cholesterol (1 mCi/ml, specific activity 44 mCi/µmol) and L-3-phosphatidyl [N-methyl-³H]choline,1,2-dipalmitoyl (1 mCi/ml, specific activity 83.0 mCi/µmol) were purchased from Amersham. Solvents were purchased from EM Science. Sephadex G50 beads were from Amersham. Buffy coats and whole human sera from normal donors were supplied by the Red Cross blood bank of NSW. Acyl-CoA:cholesterol acyltransferase (ACAT) inhibitor Sandoz 58035 (S-58035) was a gift from Drs. Nordmann and Nadelson at Sandoz Pharmaceuticals. Ficoll was supplied by Pharmacia and Nycodenz by Nycomed.

Preparation and modification of lipoproteins
Human LDL (1.019 < d < 1.063 g/ml) and lipoprotein-deficient serum (LPDS) were isolated by sequential ultracentrifugation from normolipidemic blood donors as described (29, 30). LDL was dialyzed against phosphate-buffered saline (PBS) containing EDTA (1.0 mg/ml) and chloramphenicol (0.1 mg/ml), and sterilized by 0.45 µm filtration. Acetylation of LDL (AcLDL) was performed as described (31).

Culture and loading of cells
Human monocytes (>95% pure by nonspecific esterase staining) were isolated by centrifugal elutriation from fresh white blood cell concentrates and plated at 1.5–2.0 x 10⁶ cells per 22 mm-diameter culture dish in RPMI-1640 media containing penicillin and streptomycin (50 U/ml and 50 µg/ml, respectively) at 37°C as described (14, 32, 33). Monocytes were incubated for an initial 1.5 h to establish adherence, and then the medium was exchanged with fresh RPMI-1640-containing 10% heat-inactivated whole human serum. On Day 9, the resultant human monocyte-derived macrophages were incubated with RPMI-1640 containing 10% (v/v) LPDS and 50 µg/ml AcLDL for 48–96 h to achieve enrichment with FC and CEs typical of foam cell macrophages.

Metabolic labeling
In studies using [³H]cholesterol-labeled HMFC, [³H]cholesterol (1 mCi/ml, specific activity 44 mCi/µmol) was incorporated into AcLDL as described (14) before incubation in RPMI-1640 at a final concentration of 50 µg/ml AcLDL and 2 µCi/ml [³H]cholesterol. After 48 h loading, the cells were washed and incubated overnight in RPMI-1640 containing 0.5% (w/v) BSA to allow equilibration of intracellular [³H]cholesterol prior to efflux incubations described below.

In order to analyze [³H]choline-labeled phospholipids [lysophosphatidylcholine (LPC), PC, and sphingomyelin (SPM)], cholesterol-enriched HMFCs were washed with PBS and incubated in RPMI-1640 containing [³H]choline chloride in ethanol (3 µCi/ml) and 0.1% BSA for 20 h. After incorporation, cells were washed in PBS and equilibrated for 1 h in RPMI containing 0.1% BSA, then washed before undertaking efflux incubations (34).

Cholesterol efflux
PLVs were prepared from egg PC by repeated sonication and extrusion as described (35, 36), and incubated with HMFC in RPMI-1640 at concentrations described (typically between 100–200 µg phospholipid/ml). CDs were dissolved in RPMI-1640 and generally used at 1.0 mg/ml of CD. Where PLVs containing [³H]PC were used, 40 mg of PC (400 µl) was combined with 50 µl of phosphatidyl [N-methyl-³H]choline (1 mCi/ml, 83.0 mCi/µmol) prior to preparation of PLV.

After loading with AcLDL, HMFCs were washed then incubated in 1 ml of efflux medium at 37°C. Efflux media contained either RPMI-1640 alone (±1.0 mg/ml BSA essentially fatty acid free, Sigma) or RPMI-1640 and PLV, RPMI-1640 and HP-CD ± PLV, or RPMI-1640 and TM-CD ± PLV. These media were incubated with HMFC for up to 24 h, at which time cells and media were extracted. Identical efflux and viability data were obtained with and without BSA in efflux media.

To determine mass efflux of cholesterol, both cells and media were extracted at specified times (up to 24 h). Aliquots of media were collected and centrifuged at 16,000 g for 15 min to pellet any cell debris prior to extraction of lipids. Six hundred microliters of the supernatant was extracted with 2.5 ml methanol and 5.0 ml hexane, and the hexane layer analyzed by HPLC as described below (31). HMFC monolayers were washed with PBS and lysed with 600 µl of ice-cold 0.2 M NaOH, and lipids were extracted from 400 µl aliquots of this lysate into methanol and hexane.

Mass cholesterol efflux was expressed as nmol cholesterol/culture, nmol/mg cell protein, or percent efflux (medium cholesterol divided by the sum of medium cholesterol and cellular cholesterol and CE in each culture). To quantify progressive efflux of [³H]cholesterol in kinetic studies, aliquots (100 µl) of efflux medium were removed at specified times, centrifuged to remove nonadherent cells and debris, 80 µl aliquots analyzed by scintillation counting, and cumulative efflux expressed as a percentage of total radioactivity present in cells extracted at t₀ (14).

Lipid analysis
Four milliliters of the upper hexane phase was collected, evaporated, and redissolved in HPLC mobile phase comprising acetonitrile-isopropanol-water (44:54:2, v/v/v) or acetonitrile-isopropanol (30:70, v/v) for quantification of FC and CE, respectively (25, 30). Extraction of efflux media in all experiments established that CEs were not released into the media, confirming that cellular CE decline was not attributable to cell lysis.

For HMFC radiolabeled with [³H]cholesterol, evaporated hexane extracts were redissolved with acetonitrile-isopropanol-water (44:54:2, v/v/v), and aliquots taken for HPLC analysis, scintillation counting, and TLC separation of [³H]FC and [³H]CE. Total [³H]cholesterol in the cells was determined by scintillation counting of 10 µl of NaOH lysate. Samples and standards were dried and redissolved in chloroform and spotted onto TLC plates, and FC and CE were separated with hexane-ether-glacial acetic acid (46:7:20:1, v/v/v). The proportion of label in [³H]FC and [³H]CE fractions was determined after separation by TLC using standards of FC and CE identified with 10% CuSO₄ in H₃PO₄ at 100°C.

Phospholipids were analyzed after Bligh and Dyer extraction (37) of PLV, media, cells, and cell plasma membrane fractions (see below). Phospholipid mass was determined as total phosphorous (38). Total [³H]phospholipids in each sample were determined by scintillation counting and the percentage distribution of phospholipid classes in media or cell plasma membrane fractions determined by TLC using silica-coated glass plates (5, 34). Phospholipid classes (PC, SPM, and LPC) were separated using chloroform-methanol-ammonium hydroxide (75:25:4, v/v/v) using authentic standards of PC, SPM, and LPC. Phospholipid bands were visualized by iodine vapor, scraped, extracted in methanol, and counted by scintillation. The ratio of [³H]PC-[³H]SPM-[³H]LPC on TLC was related to total [³H]phospholipid counts to derive total counts of each phospholipid per milligram of total cell protein or per milligram of plasma membrane protein as indicated.

Subcellular fractionation and isolation of plasma membranes
HMFCs were washed and scraped from culture dishes, then homogenized by shear force as previously described (39, 40). Cell lysates were layered on a 1–22% Ficoll gradient over a 45% Nycodenz cushion and centrifuged in a VTi 65.2 rotor (Beckman) at 50,000 rpm at 10°C for 90 min. Twenty-six 100 µl fractions were collected from the bottom of each tube, fractions 15–20 corresponding to plasma membranes (40), and were confirmed by plasma membrane marker enzymes alkaline phosphatase and (Na⁺, K⁺)-ATP-ase. Using this fractionation contamination with other organelles is minimal [<6.5% endoplasmic reticulum (ER) contamination assessed by glucose 6 phosphatase, and <10% Golgi contamination assessed by UDP galactose transferase]. After isolation, aliquots of plasma membrane fractions were removed for determination of protein before the remainder was subjected to Bligh and Dyer extraction and analyzed for cholesterol mass or phospholipids (see above).

Protein estimation and cell viability
The protein content of cell lysates and of LDL samples was determined in triplicate for each cell culture or sample using the bicinchoninic acid method (Sigma) with BSA as standard (29, 32). Cell viability was assessed by light microscopy, preservation of cell protein, measurement of lactate dehydrogenase release (41), and by cellular exclusion of trypan blue (32).

Data analysis
A minimum of three separate incubations were performed for each condition in each experiment, the results of which are expressed as mean ± SD of triplicate cultures, and all experiments described are representative of several, unless otherwise indicated. Where data from multiple experiments are pooled, results are expressed as mean ± SEM of "n" experiments. Simple comparisons of two independent samples used unpaired Student's t-test, and for multiple comparisons, one-way ANOVA with Bonferroni correction for multiple comparisons was used. In both instances, P < 0.05 was considered significant.

	RESULTS

TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
Side-chain substitutions modulate CD-mediated cholesterol efflux from HMFC
TM-CD and HP-CD substitutions of ß-CD were directly compared for ability to induce cholesterol efflux from HMFC at 1.0 mg/ml (i.e., 0.70 mM TM-CD and 0.65 mM HP-CD) and compared with PLV (Fig. 1) . Whereas HP-CD caused only minor cholesterol efflux, both TM-CD and PLV stimulated cholesterol efflux 2- to 3-fold. This differential efflux of cholesterol from HMFC to HP-CD and TM-CD is consistent with their known respective affinities for cholesterol (22), and indicates that at these concentrations TM-CD is superior to HP-CD as a cholesterol sink.

View larger version (12K): [in this window] [in a new window]   Fig. 1. Efflux to trimethyl-ß-CD (TM-CD) and hydroxypropyl-ß-CD (HP-CD) in the presence and absence of phospholipid vesicles (PLVs). Human monocyte-derived macrophages (HMDMs) were loaded with 50 µg/ml acetylation of LDL (AcLDL) for 96 h [human monocyte-derived foam cell macrophages (HMFC)] and then incubated with fresh efflux media for 24 h. Efflux media contained RPMI-1640 alone (RPMI), 0.65 mM HP-CD in RPMI-1640 (HP-CD), 0.70 mM TM-CD in RPMI-1640 (TM-CD), 200 µg/ml PLV, 0.65 mM HP-CD + 200 µg/ml PLV (HP-CD+PLV), or 0.70 mM TM-CD + 200 µg/ml PLV (TM-CD+PLV) in RPMI-1640. After 24 h, media were collected and lipids analyzed by HPLC, and cholesterol efflux was calculated relative to total cell cholesterol at time 0 as described in Materials and Methods. Data points represent mean ± SEM of at least four independent experiments for each condition. Conditions marked * significantly differ from RPMI (P < 0.001) and HP-CD (P < 0.01); and ¶ significantly differ from PLV (P < 0.001); and significantly differs from TM-CD+PLV (P < 0.001).

Whereas TM-CD induced more cholesterol efflux than HP-CD in the absence of PLV, TM-CD+PLV induced less efflux than HP-CD+PLV (38.1 ± 4.7% vs. 52.9 ± 5.3%, P < 0.001). TM-CD+PLV induced more cholesterol efflux than either TM-CD or PLV, but the effect was only approximately additive for efflux to TM-CD and PLV, not synergistic. This suggests differences in the mechanisms by which TM-CD and HP-CD interact with macrophages, and indicates that at these concentrations TM-CD is superior as a cholesterol sink, but HP-CD is superior as a cholesterol shuttle.

Efflux of cholesterol is dependent on the concentrations of both HP-CD and PLV
To investigate conditions optimal for cholesterol efflux to HP-CD+PLV, the concentrations of PLV and HP-CD were systematically varied. In isolation, HP-CD at concentrations between (0.0065–0.65 mM) did not achieve significant efflux, but each of these concentrations facilitated increased cholesterol efflux when PLVs (200 µg/ml) were present. At each concentration of HP-CD tested, efflux in the presence of PLV was greater than the sum of efflux to HP-CD and PLV added separately. PLV alone at all concentrations achieved modest cholesterol efflux (typically 15–20% over 24 h), but this was substantially increased in the presence of HP-CD to >50% at 24 h (unpublished observations). Increasing the concentration of PLV beyond 0.2 mg/ml did not improve cholesterol efflux to HP-CD+PLV. HP-CD in the amount of 0.65 mM and 0.2 mg/ml of PLV were used as standard combinations in subsequent experiments.

Differential depletion of FC and CE by TM-CD
To investigate why TM-CD±PLV failed to achieve as much cholesterol efflux as HP-CD+PLV, cellular lipids were analyzed in more detail. This demonstrated that TM-CD and TM-CD+PLV both depleted FC at least to the same extent as HP-CD+PLV, but depleted CE much less efficiently (Fig. 2) . TM-CD (0.7 mM) did not deplete cell CE in the absence of PLV in any experiments. The addition of PLV to TM-CD slightly increased FC depletion (range 0–24.1% greater depletion than TM-CD alone, n = 5 experiments), and in some experiments promoted mild CE depletion (range 0–18.5% depletion after 24 h, n = 5 experiments). This compares with the effect of HP-CD+PLV, which depleted cell CE by 54.5 ± 6.7% (mean ± SEM, n = 7 experiments). Increasing PLV to 0.4 mg/ml to exclude possible saturation of PLV did not improve TM-CD-mediated clearance of CE (unpublished observations).

View larger version (18K): [in this window] [in a new window]   Fig. 2. Synergistic efflux to HP-CD+PLV stimulates depletion of HMFC cholesteryl ester (CE). HMDMs were loaded with 50 µg/ml AcLDL for 96 h (HMFC), and then incubated with fresh efflux media for 24 h. Efflux media contained RPMI-1640 alone (RPMI), 0.65 mM HP-CD in RPMI-1640 (HP-CD), 0.70 mM TM-CD in RPMI-1640 (TM-CD), 200 µg/ml PLV (PLV), 0.65 mM HP-CD + 200 µg/ml PLV (HP-CD+PLV), or 0.70 mM TM-CD + 200 µg/ml PLV (TM-CD+PLV) in RPMI-1640. After 24 h, cells were collected and lipids analyzed by HPLC as described in Materials and Methods. Residual free cholesterol (FC) and CE data are expressed relative to RPMI value for each experiment, and data points represent mean ± SEM of at least three independent experiments for each condition. A: Conditions marked * significantly differ from RPMI, PLV, and HP-CD (P < 0.001); and condition significantly differs from RPMI, PLV, and HP-CD (P < 0.01). B: Condition significantly differs from RPMI, TM-CD, TM-CD+PLV (P < 0.001), PLV (P < 0.01), and HP-CD (P < 0.05).

View larger version (18K): [in this window] [in a new window]   Fig. 3. Time course of cholesterol efflux to HP-CD+PLV and TM-CD. AcLDL-loaded HMFCs were incubated with efflux medium containing RPMI-1640 only (open squares), or with added HP-CD (0.65 mM) + PLV (200 µg/ml) (closed squares) or TM-CD (0.70 mM, closed circles), for up to 24 h. Media and cells were analyzed for lipids by HPLC, and cholesterol efflux (%) was determined at each time point. A: Percent efflux. B: Residual FC in cell cultures after efflux. C: Residual CE in cell cultures after efflux.

There was rapid initial efflux of [³H]cholesterol to both HP-CD+PLV and TM-CD, and at the earliest time point (10 min), HP-CD+PLV removed at least as much cholesterol as did TM-CD (Fig. 4) . Efflux to TM-CD was nonlinear, with a declining rate between 10 min and 2 h, whereas efflux to HP-CD+PLV was almost linear over this period, indicating more limited access of cellular cholesterol to TM-CD even at early time points. At 24 h, HP-CD+PLV and TM-CD had depleted cell [³H]FC to a similar degree, but only HP-CD+PLV depleted cell [³H]CE, indicating that TM-CD failed to clear ACAT-generated CE. The specific activities (dpm/nmol) of FC and CE were unaffected by efflux incubations, which excludes substantial TM-CD-specific de novo synthesis of unlabeled FC or CE. While it remains possible that small amounts of cholesterol synthesis may occur under these conditions, substantial synthesis is unlikely to be a major contributor to preserved CE in HMFC exposed to TM-CD.

View larger version (19K): [in this window] [in a new window]   Fig. 4. Effects of HP-CD+PLV and TM-CD on initial efflux of [3H]cholesterol and specific activity of cell [3H]FC and [3H]CE. HMDMs were labeled with [3H]FC-AcLDL (final concentration 50 µg LDL protein/ml containing 2 µCi [3H]FC/ml) for 48 h, equilibrated overnight in BSA-containing RPMI-1640, and then subjected to efflux with RPMI-1640 (open square, A; black bars, B, C), HP-CD (0.65 mM) + PLV (200 µg/ml) (closed square, A; white bars, B, C), or TM-CD (0.70 mM; open circles, A; gray bars, B, C). A: Efflux of [3H]cholesterol between 0–2 h. B: Residual cell [3H]FC and [3H]CE after 24 h efflux (dpm/mg cell protein). C: Specific activity of FC and CE in cells after efflux (dpm FC/nmol FC and dpm CE/nmol CE, respectively). At the end of equilibration, before efflux (at t0), specific activities of intracellular lipids were 2.26 ± 0.66 x 104 dpm FC/nmol FC and 2.64 ± 0.38 x 104 dpm CE/nmol CE. At 24 h, the percentage of efflux to each condition was RPMI 4.2 ± 0.9%, TM-CD 21.8 ± 2.65%, and HP-CD+PLV 40.9 ± 1.3%. B: Conditions marked * significantly differ from RPMI (P < 0.01).

The concentration of TM-CD can affect apparent synergistic cholesterol efflux and depletion of cell CE
TM-CD had achieved synergistic cholesterol efflux in previous studies using low concentrations in short-term incubations of several hours duration (43). We hypothesized that if the differential CE clearance achieved by TM-CD and HP-CD related to the amount of FC removed by TM-CD, lowering the concentration of TM-CD might reduce cholesterol efflux to that achieved by HP-CD and stimulate CE depletion to TM-CD+PLV.

Without PLV, cholesterol efflux to TM-CD was diminished by reducing its concentration (0.007–0.7 mM), but TM-CD alone did not decrease CE (unpublished observations). In the presence of PLV, decreasing the concentration of TM-CD promoted depletion of CE but diminished depletion of FC (Fig. 5) . Consequently, overall cholesterol efflux to TM-CD+PLV was similar at low and high concentrations of TM-CD because of greater FC depletion at higher concentrations. These data confirmed that the depletion of FC and CE can be dissociated, and establish that depletion of CE is inhibited by higher concentrations of TM-CD.

View larger version (23K): [in this window] [in a new window]   Fig. 5. CE depletion by TM-CD+PLV is stimulated by low concentrations of TM-CD. HMFCs were incubated with TM-CD (0–0.70 mM) + PLV (200 µg/ml) for 24 h. As a positive control, HMFCs were also incubated with HP-CD (0.65 mM) + PLV (200 µg/ml) (HP-CD+PLV). Cell FC and CE and medium cholesterol were determined for each culture by HPLC, and percentage cholesterol efflux calculated for each culture as described in Materials and Methods. Where error bar is not visible, it is obscured by the symbol. A: Percentage cholesterol efflux at 24 h. B: Residual cell FC at 24 h. C: Residual cell CE at 24 h. A: Conditions * significantly differ from RPMI and PLV (P < 0.001), condition # significantly differs from RPMI (P < 0.05), and condition significantly differs from all other conditions (P < 0.001). B: Conditions * differ from RPMI and PLV (P < 0.001), and condition ¶ differs from RPMI (P < 0.01). C: Conditions * differ from RPMI, PLV, TM-0.70 (P < 0.001), and condition differs from TM-0.70+PLV (P < 0.01).

Prior exposure to TM-CD does not inhibit efflux to HP-CD+PLV
To determine if 0.7 mM TM-CD caused irreversible changes to the composition or structure of HMFC plasma membrane, cells were preincubated with either RPMI-1640 or TM-CD for 1 h before measuring efflux to HP-CD+PLV for 24 h (Fig. 6) . TM-CD did not significantly inhibit subsequent cholesterol efflux (unpublished observations) or depletion of FC or CE by HP-CD+PLV.

View larger version (19K): [in this window] [in a new window]   Fig. 6. Preincubation with TM-CD does not inhibit cholesterol efflux to HP-CD+PLV. HMFCs were incubated with RPMI-1640 (RPMI), or HP-CD (0.65 mM) + PLV (200 µg/ml) (HP-CD+PLV) for 24 h. Parallel cultures of HMFC were also preincubated with either RPMI-1640 alone or with TM-CD (0.70 mM) for 1 h before washing and incubating with HP-CD+PLV for 24 h. Cell FC and CE and medium cholesterol were determined for each culture after 24 h by HPLC. A: Residual cell FC at 24 h. B: Residual cell CE at 24 h. All three HP-CD+PLV-incubations generated identical efflux at 24 h (unpublished observations).

Differential CE depletion to TM-CD and HP-CD+PLV requires ongoing cholesterol esterification in the presence of TM-CD
CEs synthesized in cells are subject to a continuous cycle of hydrolysis via neutral CE hydrolase and reesterification via ACAT (45). Consequently, the inability of TM-CD to mediate CE clearance, despite FC clearance, could be due to inhibition of CE hydrolysis or require ongoing cholesterol esterification via ACAT, and this was investigated by incubating cells with the ACAT inhibitor S-58035 during efflux. Under these conditions, RPMI, TM-CD±PLV, and HP-CD+PLV all caused equivalent depletion of cell CE (Fig. 7) . This suggests that TM-CD does not inhibit hydrolysis of CE, and that cell CEs remaining after TM-CD exposure require synthesis by ACAT. They also indicate that HP-CD+PLV does not stimulate CE hydrolysis, as cells exposed to ACAT inhibitor contained similar residual CEs after incubation with RPMI (12.7 ± 0.90 nmol/mg cell protein) or HP-CD+PLV (10.7 ± 2.4 nmol/mg cell protein).

View larger version (28K): [in this window] [in a new window]   Fig. 7. Acyl-CoA:cholesterol acyltransferase (ACAT) inhibition during efflux permits CE depletion by TM-CD. HMFCs were generated by incubating HMDM with AcLDL (T0), then incubated for 24 h with TM-CD (0.70 mM), TM-CD (0.70 mM) + PLV (200 µg/ml) (TM-CD+PLV), and HP-CD (0.65 mM) + PLV (200 µg/ml) (HP-CD+PLV) in the presence (gray bars) or absence (solid bars) of 5.0 µg/ml ACAT inhibitor S-58035. Cell FC and CE were determined for each culture by HPLC as described in Materials and Methods. After 24 h in RPMI with ACAT inhibitor, cell CE content was 12.7 ± 0.9 nmol/mg cell protein, which was not significantly different from that of TM-CD, TM-CD+PLV, or HP-CD+PLV, as shown in B. Conditions marked * and ¶ are significantly different from T0 (respectively P < 0.05 and P < 0.001).

HP-CD acting as a sink achieves depletion of cell CE
Cells were incubated with higher concentrations of HP-CD sufficient to stimulate cholesterol efflux even without PLV (Fig. 8) . HP-CD differed from TM-CD as it promoted significant CE clearance at high concentrations in the absence of PLV, i.e., when acting as a sink. In the presence of PLV, CE depletion was maximal at 0.65 mM HP-CD, whereas FC depletion increased with increasing concentrations of HP-CD. Thus, removal of cholesterol by CDs does not in itself necessarily impede depletion of cellular CE, and suggests a qualitative difference in the response to TM-CD and HP-CD.

View larger version (17K): [in this window] [in a new window]   Fig. 8. HP-CD mediates CE clearance at concentrations sufficient to cause depletion of cell FC. HMFCs were incubated with RPMI-1640 control, HP-CD alone (0.65–5.2 mM) (open circles), or HP-CD (0.65–5.2 mM) + PLV (200 µg/ml) (closed circles). A: Residual FC. B: Residual CE. Values marked ¶ and * significantly differ from control RPMI (P < 0.01 and P < 0.02, respectively).

	DISCUSSION

TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
These studies demonstrate that the plasma membrane is a major rate-limiting factor for cholesterol efflux and CE depletion from HMFC, and establish differential CE depletion as an important qualitative difference in the consequences of efflux to CDs with different affinity to cholesterol. This demonstrates for the first time that the properties of an acceptor that are optimal for depletion of FC need not be optimal for depletion of CE and overall cholesterol clearance, and that FC depletion and CE depletion can be dissociated.

CDs are sterol-solubilizing agents (21). Their efficient ability to access plasma membrane cholesterol has been attributed to a combination of properties: their small size that increases the frequency of collisions with desorbed cholesterol molecules; their ability to directly access the plasma membrane, evading large surface structures that limit access to comparatively larger PLVs; and their excellent water solubility that facilitates penetration of the extracellular water layer (22, 48). Their interaction with PLVs during the process of shuttling combines efficient CD-mediated solubilization of membrane cholesterol with the greater cholesterol-binding capacity of PLV, and relies upon the relatively low affinity CDs have for cholesterol (K_a).

The determination of factors that restrict efflux from primary HMFC has hitherto been indirect. This has substantially underestimated the importance of the plasma membrane because of the relative inability of physiological acceptors to cause significant cholesterol efflux. In our laboratory, saturating concentrations of apoA-I and HDL cause modest depletion of CE from HMFC (<15% per 24 h), but this depletion is commensurate with the limited cholesterol efflux from primary HMFC achieved by these agents (total efflux 10–20% at 24 h). In contrast, HP-CD+PLV depleted CE by >50% over 24 h. This effect is consistent with either direct stimulation of CE hydrolysis or CE depletion secondary to efficient removal of plasma membrane cholesterol. Under conditions in which ACAT was inhibited, equal depletion of CE was achieved with HP-CD+PLV and control medium RPMI-1640. This indicates that HP-CD+PLV depletes CE by stimulating cholesterol efflux, not by stimulating CE hydrolysis.

The detection of synergy between CD and PLV predictably requires a relatively low level of efflux to individual components; however, previous studies have not described any important qualitative differences in the consequences of efflux to TM-CD acting as a sink and HP-CD+PLV where the CD acts as a shuttle (26, 43). Differences between this study and previous reports may be due to our use of primary HMFCs, which are inherently resistant to cholesterol efflux and may be more sensitive to redistributions of plasma membrane cholesterol, and our deliberate use of net CE clearance as one of the measures of efficacy. The latter is important in HMFCs, given the slow CE hydrolysis in these cells, which cannot be assessed from experiments of <8 h duration.

The differences in the effects of low- and high-affinity CDs are also important because of recent application of these agents to study diverse biological phenomena, including the actions of raft-related proteins. A number of studies have manipulated cellular and plasma membrane cholesterol by the use of high concentrations of high-affinity CDs such as methyl CD (49), and high concentrations of HP-CD (50) (10- to 80-fold higher than the present study). Given our observations with nontoxic and low-dose CDs, we anticipate that the use of such high concentrations of high-affinity CDs acting as sinks may dramatically perturb normal cholesterol trafficking pathways and CDs, because a class cannot be assumed to be biologically equivalent.

It is most notable in the present studies that TM-CD permits ongoing cholesterol reesterification despite concurrent depletion of FC, as previous studies have shown a very close relationship between plasma membrane cholesterol content and cholesterol esterification in the ER (51). This suggests that TM-CD may remove certain plasma membrane pools of FC that do not affect ACAT activity, or may remove plasma membrane cholesterol from ACAT-inaccessible pools and redeliver it to ACAT-accessible pools while still causing net FC depletion. Previous studies have shown that solutions of CDs that are saturated with respect to cholesterol can deliver cholesterol to macrophages, and that this cholesterol can be esterified by ACAT (14, 43, 52).

Net efflux to TM-CD was modestly increased by ACAT inhibition, but greater CE clearance occurred at the expense of diminished FC clearance, suggesting that other unknown properties of TM-CD restrict cholesterol efflux. It is unlikely that TM-CD cannot transfer cholesterol to PLV, as a number of agents with high cholesterol affinity shuttle cholesterol to PLV very effectively (43), and the present study clearly shows synergy between lower concentrations of TM-CD and PLV in stimulating cholesterol efflux and CE depletion.

The apparent dissociation of FC and CE depletion with TM-CD may occur via several routes. It is known that plasma membrane pools of cholesterol are structurally and kinetically heterogeneous (53, 54). TM-CD may remove cholesterol from domains within the plasma membrane where it is more strongly bound (e.g., rafts), and subsequently allow cholesterol to reenter the plasma membrane at other sites with greater access to ACAT (54). Our data showing much greater depletion of plasma membrane cholesterol by TM-CD (±PLV) than by HP-CD+PLV support the possibility that TM-CD accesses pools of plasma membrane cholesterol that are not accessed by HP-CD. The removal of selected pools of plasma membrane cholesterol, which may represent only a small proportion of the total, has been shown to affect intracellular protein translocation (55). It is therefore possible that such cholesterol depletion may directly affect the location of ACAT or its regulatory proteins inside the cell. Such depletion may also perturb other cholesterol-regulatory proteins, such as the more recently described ABCA1.

Using [³H]cholesterol-labeled cells (Fig. 4), it appears that neither CE mass nor CE specific activity were increased by TM-CD (relative to control incubations), indirectly indicating that ACAT activity is not increased by this agent; however, we have not directly measured changes to ACAT activity induced by CDs. Interpretation of ACAT activity using conventional assays would be complicated by the solubilizing effects of CDs on ACAT substrates (cholesterol and fatty acids) when these are added to culture media, which will indirectly alter apparent ACAT activity. Direct experimental measurement of ACAT activity in whole cells, and investigating if CDs affect cellular fatty acid metabolism and directly regulate ACAT activity, are important future investigations.

Selective depletion of SPM from the plasma membrane can potentially perturb the condensing and cholesterol-binding properties of sites preferentially enriched in SPM (such as membrane rafts). By analogy with the effects of sphingomyelinase treatment of cells, this would be expected to increase cholesterol internalization, traffic to the ER, and cytoplasmic esterification (46). We did not identify significant depletion of SPM from the plasma membrane under these experimental conditions. Recent studies show that the rate of cellular SPM synthesis is markedly increased by depletion of cell cholesterol by CDs (56). Consequently, depletion of SPM in cell membranes would require substantial SPM efflux that exceeds the cellular capacity for synthesis and replenishment.

In summary, high-affinity CDs appear to dissociate the link between plasma membrane cholesterol concentration, net cholesterol efflux, and intracellular cholesterol esterification. It is likely that plasma membrane cholesterol is an important regulator of net cholesterol efflux and CE metabolism in human macrophages.

	ACKNOWLEDGMENTS

 
This work was supported by the National Health and Medical Research Council (NHMRC project grant 980595) and the Vincent Fairfax Family Trust. W.J. is a Principal Research Fellow of the NHMRC. Tim Sloane is thanked for excellent technical assistance.

Manuscript received December 11, 2002 and in revised form March 17, 2003.

	REFERENCES

TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

1. Bjorkhem, I., O. Andersson, U. Diczfalusy, B. Sevastik, and R-J. Xiu. 1994. Atherosclerosis and sterol 27-hydroxylase: evidence for a role of this enzyme in elimination of cholesterol from human macrophages. Proc. Natl. Acad. Sci. USA. 91: 8592–8596.[Abstract/Free Full Text]

2. Fielding, C. J., and P. E. Fielding. 1995. Molecular physiology of reverse cholesterol transport. J. Lipid Res. 36: 211–228.[Abstract]

3. Rothblat, G. H., M. de la Llera-Moya, V. Atger, G. Kellner-Weibel, D. L. Williams, and M. C. Phillips. 1999. Cell cholesterol efflux: integration of old and new observations provides new insights. J. Lipid Res. 40: 781–796.[Abstract/Free Full Text]

4. Westman, J., B. Kallin, I. Bjorkhem, J. Nilsson, and U. Diczfalusy. 1998. Sterol 27-hydroxylase- and apo A-I/phospholipid-mediated efflux of cholesterol from cholesterol-laden macrophages: evidence for an inverse relation between the two mechanisms. Arterioscler. Thromb. Vasc. Biol. 18: 554–561.[Abstract/Free Full Text]

5. Gillotte, K. L., M. Zaiou, S. Lund-Katz, G. M. Anantharamaiah, P. Holvoet, A. Dhoest, M. N. Palgunachari, J. P. Segrest, K. H. Weisgraber, G. H. Rothblat, and M. C. Phillips. 1999. Apolipoprotein-mediated plasma membrane microsolubilization. Role of lipid affinity and membrane penetration in the efflux of cellular cholesterol and phospholipid. J. Biol. Chem. 274: 2021–2028.[Abstract/Free Full Text]

6. Acton, S., A. Rigotti, K. T. Landschulz, S. Xu, H. H. Hobbs, and M. Krieger. 1996. Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science. 271: 518–520.[Abstract]

7. Bodzioch, M., E. Orso, J. Klucken, T. Langmann, A. Bottcher, W. Diederich, W. Drobnik, S. Barlage, C. Buchler, M. Porsch-Ozcurumez, W. E. Kaminski, H. W. Hahmann, K. Oette, G. Rothe, C. Aslanidis, K. J. Lackner, and G. Schmitz. 1999. The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease. Nat. Genet. 22: 347–351.[CrossRef][Medline]

8. Brooks-Wilson, A., M. Marcil, S. M. Clee, L. H. Zhang, K. Roomp, M. van Dam, L. Yu, C. Brewer, J. A. Collins, H. O. Molhuizen, O. Loubser, B. F. Ouelette, K. Fichter, K. J. Ashbourne-Excoffon, C. W. Sensen, S. Scherer, S. Mott, M. Denis, D. Martindale, J. Frohlich, K. Morgan, B. Koop, S. Pimstone, J. J. Kastelein, and M. R. Hayden. 1999. Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. Nat. Genet. 22: 336–345.[CrossRef][Medline]

9. Lawn, R. M., D. P. Wade, M. R. Garvin, X. Wang, K. Schwartz, J. G. Porter, J. J. Seilhamer, A. M. Vaughan, and J. F. Oram. 1999. The Tangier disease gene product ABC1 controls the cellular apolipoprotein-mediated lipid removal pathway. J. Clin. Invest. 104: R25–R31.

10. Rust, S., M. Rosier, H. Funke, J. Real, Z. Amoura, J. C. Piette, J. F. Deleuze, H. B. Brewer, N. Duverger, P. Denefle, and G. Assmann. 1999. Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1. Nat. Genet. 22: 352–355.[CrossRef][Medline]

11. Jian, B., M. de la Llera-Moya, Y. Ji, N. Wang, M. C. Phillips, J. B. Swaney, A. R. Tall, and G. H. Rothblat. 1998. Scavenger receptor class B type I as a mediator of cellular cholesterol efflux to lipoproteins and phospholipid acceptors. J. Biol. Chem. 273: 5599–5606.[Abstract/Free Full Text]

12. Westman, J. A., C. Roobol, L. A. Carlson, and E. Wulfert. 1995. Efflux of cholesterol from cholesterol laden human monocyte derived macrophages by complexes of apolipoprotein A-I or proapolipoprotein A-I and phosphatidylcholine. Nutr. Metab. Cardiovasc. Dis. 5: 297–305.

13. Graham, A., A. D. Angell, C. A. Jepson, S. J. Yeaman, and D. G. Hassall. 1996. Impaired mobilisation of cholesterol from stored cholesteryl esters in human (THP-1) macrophages. Atherosclerosis. 120: 135–145.[CrossRef][Medline]

14. Kritharides, L., A. Christian, G. Stoudt, D. Morel, and G. H. Rothblat. 1998. Cholesterol metabolism and efflux in human THP-1 macrophages. Arterioscler. Thromb. Vasc. Biol. 18: 1589–1599.[Abstract/Free Full Text]

15. Mahlberg, F. H., and G. H. Rothblat. 1992. Cellular cholesterol efflux. Role of cell membrane kinetic pools and interaction with apolipoproteins AI, AII, and Cs. J. Biol. Chem. 267: 4541–4550.[Abstract/Free Full Text]

16. Mahlberg, F. H., J. M. Glick, S. Lund-Katz, and G. H. Rothblat. 1991. Influence of apolipoproteins A-I, A-II and C on the metabolism of membrane and lysosomal cholesterol in macrophages. J. Biol. Chem. 266: 19930–19937.[Abstract/Free Full Text]

17. Tabas, I., W. J. Rosoff, and G. C. Boykow. 1988. Acyl coenzyme A:cholesterol acyl transferase in macrophages utilizes a cellular pool of cholesterol oxidase-accessible cholesterol as substrate. J. Biol. Chem. 263: 1266–1272.[Abstract/Free Full Text]

18. Lange, Y., J. Ye, M. Rigney, and T. L. Steck. 1999. Regulation of endoplasmic reticulum cholesterol by plasma membrane cholesterol. J. Lipid Res. 40: 2264–2270.[Abstract/Free Full Text]

19. Liscum, L., and N. J. Munn. 1999. Intracellular cholesterol transport. Biochim. Biophys. Acta. 1438: 19–37.[Medline]

20. Tabas, I. 2000. Cholesterol and phospholipid metabolism in macrophages. Biochim. Biophys. Acta. 1529: 164–174.[Medline]

21. Rawyler, A., and P. A. Siegenthaler. 1996. Cyclodextrins: a new tool for the controlled lipid depletion of thylakoid membranes. Biochim. Biophys. Acta. 1278: 89–97.[Medline]

22. Kilsdonk, E. P., P. G. Yancey, G. W. Stoudt, F. W. Bangerter, W. J. Johnson, M. C. Phillips, and G. H. Rothblat. 1995. Cellular cholesterol efflux mediated by cyclodextrins. J. Biol. Chem. 270: 17250–17256.[Abstract/Free Full Text]

23. Yancey, P. G., W. V. Rodrigueza, E. P. C. Kilsdonk, G. W. Stoudt, W. J. Johnson, M. C. Phillips, and G. H. Rothblat. 1996. Cellular cholesterol efflux mediated by cyclodextrins. Demonstration of kinetic pools and mechanism of efflux. J. Biol. Chem. 271: 16026–16034.[Abstract/Free Full Text]

24. Ohvo, H., and J. P. Slotte. 1996. Cyclodextrin-mediated removal of sterols from monolayers: effects of sterol structure and phospholipids on desorption rate. Biochemistry. 35: 8018–8024.[CrossRef][Medline]

25. Kritharides, L., M. Kus, A. J. Brown, W. Jessup, and R. T. Dean. 1996. Hydroxypropyl-beta-cyclodextrin-mediated efflux of 7-ketocholesterol from macrophage foam cells. J. Biol. Chem. 271: 27450–27455.[Abstract/Free Full Text]

26. Atger, V. M., M. de la Llera Moya, G. W. Stoudt, W. V. Rodrigueza, M. C. Phillips, and G. H. Rothblat. 1997. Cyclodextrins as catalysts for the removal of cholesterol from macrophage foam cells. J. Clin. Invest. 99: 773–780.[Medline]

27. Rodrigueza, W., K. J. Williams, G. H. Rothblat, and M. C. Phillips. 1997. Remodelling and shuttling: mechanisms for the synergistic effects between different acceptor particles in the mobilization of cellular cholesterol. Arterioscler. Thromb. Vasc. Biol. 17: 383–393.[Abstract/Free Full Text]

28. Williams, K. J., M. C. Phillips, and W. V. Rodrigueza. 1998. Structural and metabolic consequences of liposome-lipoprotein interaction. Adv. Drug Deliv. Rev. 32: 31–43.[CrossRef][Medline]

29. Jessup, W., E. L. Mander, and R. T. Dean. 1992. The intracellular storage and turnover of apolipoprotein B of oxidized LDL in macrophages. Biochim. Biophys. Acta. 1126: 167–177.[Medline]

30. Kritharides, L., W. Jessup, J. Gifford, and R. T. Dean. 1993. A method for defining the stages of low-density lipoprotein oxidation by the separation of cholesterol- and cholesteryl ester-oxidation products using HPLC. Anal. Biochem. 213: 79–89.[CrossRef][Medline]

31. Kritharides, L., W. Jessup, E. L. Mander, and R. T. Dean. 1995. Apolipoprotein A-I-mediated efflux of sterols from oxidized LDL-loaded macrophages. Arterioscler. Thromb. Vasc. Biol. 15: 276–289.[Abstract/Free Full Text]

32. Rees, D., T. Sloane, W. Jessup, R. T. Dean, and L. Kritharides. 1999. Apolipoprotein A-I stimulates secretion of apolipoprotein E by foam cell macrophages. J. Biol. Chem. 274: 27925–27933.[Abstract/Free Full Text]

33. Garner, B., R. T. Dean, and W. Jessup. 1994. Human macrophage-mediated oxidation of low-density lipoprotein is delayed and independent of superoxide production. Biochem. J. 301: 421–428.

34. Gelissen, I. C., K. A. Rye, A. J. Brown, R. T. Dean, and W. Jessup. 1999. Oxysterol efflux from macrophage foam cells: the essential role of acceptor phospholipid. J. Lipid Res. 40: 1636–1646.[Abstract/Free Full Text]

35. Johnson, W. J., F. H. Mahlberg, G. K. Chacko, M. C. Phillips, and G. H. Rothblat. 1988. The influence of cellular and lipoprotein cholesterol contents on the flux of cholesterol between fibroblasts and high density lipoprotein. J. Biol. Chem. 263: 14099–14106.[Abstract/Free Full Text]

36. Rodrigueza, W. V., J. J. Wheeler, S. K. Klimuk, C. N. Kitson, and M. J. Hope. 1995. Transbilayer movement and net flux of cholesterol and cholesterol sulfate between liposomal membranes. Biochemistry. 34: 6208–6217.[CrossRef][Medline]

37. Bligh, E. G., and W. J. Dyer. 1959. A rapid method of total lipid extraction and purification. Can. J. Biochem. 37: 911–917.[Medline]

38. Sokoloff, L., and G. H. Rothblat. 1974. Sterol to phospholipid molar ratios of L cells with qualitative and quantitative variations in cellular sterol. Proc. Soc. Exp. Biol. Med. 146: 1166–1172.[CrossRef][Medline]

39. Mander, E., W. Jessup, and R. Dean. 1994. Apolipoprotein B of oxidized LDL accumulates in the lysosomes of macrophages. Biochim. Biophys. Acta. 1212: 80–92.[Medline]

40. Gaus, K., R. T. Dean, L. Kritharides, and W. Jessup. 2001. Inhibition of cholesterol efflux by 7-ketocholesterol: comparison between cells, plasma membrane vesicles, and liposomes as cholesterol donors. Biochemistry. 40: 13002–13014.[CrossRef][Medline]

41. Dean, R. T., W. Hylton, and A. C. Allison. 1979. Induction of macrophage lysosomal enzyme secretion by agents acting at the plasma membrane. Exp. Cell Biol. 47: 454–462.[Medline]

42. Kruth, H. S., S. I. Skarlatos, P. M. Gaynor, and W. Gamble. 1994. Production of cholesterol-enriched nascent high density lipoproteins by human monocyte-derived macrophages is a mechanism that contributes to macrophage cholesterol efflux. J. Biol. Chem. 269: 24511–24518.[Abstract/Free Full Text]

43. Christian, A. E., H. S. Byun, N. Zhong, M. Wanunu, T. Marti, A. Furer, F. Diederich, R. Bittman, and G. H. Rothblat. 1999. Comparison of the capacity of beta-cyclodextrin derivatives and cyclophanes to shuttle cholesterol between cells and serum lipoproteins. J. Lipid Res. 40: 1475–1482.[Abstract/Free Full Text]

44. Rodrigueza, W. V., K. J. Williams, G. H. Rothblat, and M. C. Phillips. 1997. Remodeling and shuttling. Mechanisms for the synergistic effects between different acceptor particles in the mobilization of cellular cholesterol. Arterioscler. Thromb. Vasc. Biol. 17: 383–393.

45. Brown, M. S., Y. K. Ho, and J. L. Goldstein. 1980. The cholesteryl ester cycle in macrophage foam cells. J. Biol. Chem. 255: 9344–9352.[Free Full Text]

46. Slotte, J. P., and E. L. Bierman. 1988. Depletion of plasma-membrane sphingomyelin rapidly alters the distribution of cholesterol between plasma membranes and intracellular cholesterol pools in cultured fibroblasts. Biochem. J. 250: 653–658.[Medline]

47. Leventis, R., and J. R. Silvius. 2001. Use of cyclodextrins to monitor transbilayer movement and differential lipid affinities of cholesterol. Biophys. J. 81: 2257–2267.[Medline]

48. Yancey, P. G., W. V. Rodrigueza, E. P. C. Kilsdonk, G. W. Stoudt, W. J. Johnson, M. C. Phillips, and G. H. Rothblat. 1996. Cellular cholesterol efflux mediated by cyclodextrins. Demonstration of kinetic pools and mechanism of efflux. J. Biol. Chem. 271: 16026–16034.

49. Scheiffele, P., P. Verkade, A. M. Fra, H. Virta, K. Simons, and E. Ikonen. 1998. Caveolin 1 and 2 in the exocytic pathway of MDCK cells. J. Cell Biol. 140: 795–806.[Abstract/Free Full Text]

50. Neufeld, E. B., A. M. Cooney, J. Pitha, E. A. Dawidowicz, N. K. Dwyer, P. G. Pentchev, and E. J. Blanchette-Mackie. 1996. Intracellular trafficking of cholesterol monitored with a cyclodextrin. J. Biol. Chem. 271: 21604–21613.[Abstract/Free Full Text]

51. Lange, Y., J. Ye, M. Rigney, and T. Steck. 2000. Cholesterol movement in Niemann-Pick type C cells and in cells treated with amphiphiles. J. Biol. Chem. 275: 17468–17475.[Abstract/Free Full Text]

52. Christian, A. E., M. P. Haynes, M. C. Phillips, and G. H. Rothblat. 1997. Use of cyclodextrins for manipulating cellular cholesterol content. J. Lipid Res. 38: 2264–2272.[Abstract]

53. Haynes, M. P., M. C. Phillips, and G. H. Rothblat. 2000. Efflux of cholesterol from different cellular pools. Biochemistry. 39: 4508–4517.[CrossRef][Medline]

54. Simons, K., and E. Ikonen. 2000. How cells handle cholesterol. Science. 290: 1721–1726.[Abstract/Free Full Text]

55. Ridgway, N. D., T. A. Lagace, H. W. Cook, and D. M. Byers. 1998. Differential effects of sphingomyelin hydrolysis and cholesterol transport on oxysterol-binding protein phosphorylation and Golgi localization. J. Biol. Chem. 273: 31621–31628.[Abstract/Free Full Text]

56. Leppimaki, P., R. Kronqvist, and J. P. Slotte. 1998. The rate of sphingomyelin synthesis de novo is influenced by the level of cholesterol in cultured human skin fibroblasts. Biochem. J. 335: 285–291.

CiteULike

Complore

Connotea

Del.icio.us

Digg

Reddit

Technorati

This article has been cited by other articles:

				K. Gaus, M. Rodriguez, K. R. Ruberu, I. Gelissen, T. M. Sloane, L. Kritharides, and W. Jessup Domain-specific lipid distribution in macrophage plasma membranes J. Lipid Res., July 1, 2005; 46(7): 1526 - 1538. [Abstract] [Full Text] [PDF]

				E. N. Glaros, W. S. Kim, C. M. Quinn, J. Wong, I. Gelissen, W. Jessup, and B. Garner Glycosphingolipid Accumulation Inhibits Cholesterol Efflux via the ABCA1/Apolipoprotein A-I Pathway: 1-PHENYL-2-DECANOYLAMINO-3-MORPHOLINO-1-PROPANOL IS A NOVEL CHOLESTEROL EFFLUX ACCELERATOR J. Biol. Chem., July 1, 2005; 280(26): 24515 - 24523. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) All Versions of this Article: M200464-JLR200v1 44/6/1156    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Liu, S. M. Articles by Kritharides, L. Search for Related Content PubMed PubMed Citation Articles by Liu, S. M. Articles by Kritharides, L. Social Bookmarking                      What's this?